Literature DB >> 1397890

Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation.

K G Benner1, R G Lee, E B Keeffe, R R Lopez, A W Sasaki, C W Pinson.   

Abstract

Four patients who underwent transplantation for hepatitis B virus-related liver disease developed rapidly progressive liver failure attributable to recurrent hepatitis B disease typified by hyperbilirubinemia and distinctive hepatocyte ballooning and progressive fibrosis consistent with recently reported fibrosing cholestatic hepatitis. Among these four patients, the mean interval from transplantation to redocumentation of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) was 5 months, to development of malaise and jaundice 6 months, to histological diagnosis 7 months, and to graft failure 8 months. The only patient who underwent retransplantation had accelerated recurrence of the same syndrome with biopsy documentation 1 month later and graft failure 2 months later. Distinctive histological features included confluent hepatocellular ballooning and progressive periportal fibrosis followed by lobular collapse over 4-6 weeks without significant inflammation. Immunohistochemical staining showed marked HBsAg and hepatitis B core antigen (HBcAg) immunoreactivity. The rapid development of cytolytic hepatocellular necrosis and lobular collapse with prominent HBcAg immunoreactivity without significant inflammation suggests a cytolytic rather than immune pathogenesis for this unique and devastating form of recurrent hepatitis B that might better be termed "fibrosing cytolytic hepatitis."

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397890     DOI: 10.1016/0016-5085(92)91521-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

1.  Hepatitis B virus infection and liver transplantation.

Authors:  N A Terrault; T L Wright
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

2.  Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus.

Authors:  Philip Meuleman; Louis Libbrecht; Stefan Wieland; Rita De Vos; Nagy Habib; Anna Kramvis; Tania Roskams; Geert Leroux-Roels
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  Acute hepatitis C infection in a renal transplant recipient: primacy of the liver or kidney?

Authors:  Mohammed Mahdi Althaf; Mohamed Said Abdelsalam; Mohamed Rashwan; Quaid Nadri
Journal:  BMJ Case Rep       Date:  2014-06-06

Review 4.  Fibrosing cholestatic hepatitis in renal transplant recipient with CMV infection: a case report.

Authors:  S K Agarwal; V Kalra; Amit Dinda; S Gupta; S C Dash; D Bhowmik; S C Tiwari
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 5.  Hepatitis B virus large surface protein: function and fame.

Authors:  Yuri Churin; Martin Roderfeld; Elke Roeb
Journal:  Hepatobiliary Surg Nutr       Date:  2015-02       Impact factor: 7.293

6.  Loss of HBsAg and antiviral treatment: from basics to clinical significance.

Authors:  Yuecheng Yu; Jinlin Hou; Masao Omata; Yue Wang; Lanjuan Li
Journal:  Hepatol Int       Date:  2014-01-03       Impact factor: 6.047

7.  Fibrosing cholestatic hepatitis in a kidney transplant recipient with hepatitis C virus.

Authors:  Takahiro Shinzato; Taro Kubo; Toshihiro Shimizu; Koji Nanmoku; Takashi Yagisawa
Journal:  CEN Case Rep       Date:  2019-01-02

Review 8.  Controversies in patient selection for liver transplantation.

Authors:  E B Keeffe; C O Esquivel
Journal:  West J Med       Date:  1993-11

9.  Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis.

Authors:  Shu-Yuan Xiao; Liang Lu; Hanlin L Wang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

10.  Successful treatment of fibrosing cholestatic hepatitis following kidney transplantation with allogeneic hematopoietic stem cell transplantation: a case report.

Authors:  Dong Liang Li; Jian Fang; Zhiyong Zheng; Weizhen Wu; Zhixian Wu
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.